Ciclosporin - Sublimity Therapeutics

Drug Profile

Ciclosporin - Sublimity Therapeutics

Alternative Names: AlloCol; Cyclosporin - Sublimity Therapeutics; Cyclosporine - Sublimity Therapeutics; Cyclosporine A - Sublimity Therapeutics; CyCol; CyCron; CyLow; Oral cyclosporine - Sublimity Therapeutics; STI 0529

Latest Information Update: 03 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sigmoid Pharma
  • Developer Sublimity Therapeutics
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes - Graft-versus-host disease; Transplant rejection; Ulcerative colitis

Highest Development Phases

  • Phase II Ulcerative colitis
  • No development reported Crohn's disease; Graft-versus-host disease; Psoriasis; Transplant rejection

Most Recent Events

  • 30 Jul 2018 Sublimity Therapeutics plans a global phase IIb trial for Ulcerative colitis
  • 22 May 2018 Sigmoid Pharma is now called Sublimity Therapeutics
  • 22 May 2018 Sublimity Therapeutics plans a global phase IIb trial for Ulcerative colitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top